Treatment of Shingles (Herpes Zoster)
Start oral antiviral therapy immediately—ideally within 72 hours of rash onset—with valacyclovir 1000 mg three times daily or famciclovir 500 mg three times daily for 7–10 days, continuing until all lesions have completely scabbed. 1
Antiviral Therapy: First-Line Treatment
Oral Antiviral Options
For uncomplicated herpes zoster in immunocompetent adults, three oral antivirals are effective:
- Valacyclovir 1000 mg three times daily for 7 days (preferred due to superior bioavailability and convenient dosing) 1, 2
- Famciclovir 500 mg three times daily for 7 days (equally effective with better adherence than acyclovir) 1, 2
- Acyclovir 800 mg five times daily for 7–10 days (effective but requires more frequent dosing, which may reduce adherence) 1, 3, 2
Critical timing: Antiviral therapy is most effective when initiated within 48–72 hours of rash onset, reducing acute pain duration, accelerating lesion healing, and preventing postherpetic neuralgia. 1, 3, 4 However, treatment should still be started even after 72 hours if new lesions are still forming or in high-risk patients. 1
Treatment duration: Continue therapy until all lesions have completely scabbed—this is the key clinical endpoint, not an arbitrary 7-day period. 1 In immunocompromised patients, treatment may need to extend well beyond 7–10 days as lesions develop over longer periods (7–14 days) and heal more slowly. 1
Indications for Intravenous Acyclovir
Switch to IV acyclovir 10 mg/kg every 8 hours when any of the following are present:
- Disseminated herpes zoster (≥3 dermatomes, visceral involvement, or hemorrhagic lesions) 1
- Severe immunosuppression (active chemotherapy, HIV with low CD4 count, organ transplant) 1
- CNS complications (encephalitis, meningitis, Guillain-Barré syndrome) 1
- Complicated facial/ophthalmic disease with risk of cranial nerve involvement 1
- Inability to absorb oral medication 1
- Lack of clinical improvement after 7–10 days of appropriate oral therapy (suspect acyclovir resistance) 1
Continue IV therapy for a minimum of 7–10 days and until clinical resolution (all lesions scabbed). 1
Renal Dose Adjustments
Mandatory dose reductions are required for renal impairment to prevent nephrotoxicity:
| Creatinine Clearance | Valacyclovir Dose | Famciclovir Dose |
|---|---|---|
| 30–49 mL/min | 1000 mg every 12h | 500 mg every 12h |
| 10–29 mL/min | 1000 mg every 24h | 500 mg every 24h |
| <10 mL/min | 500 mg every 24h | 250 mg every 24h |
Baseline renal function must be assessed before starting therapy, with monitoring once or twice weekly during IV acyclovir. 1 Ensure adequate hydration to reduce crystalluria risk. 1
Important Caveats
- Topical antivirals are substantially less effective than systemic therapy and should not be used. 1
- Short-course regimens (1–3 days) designed for genital herpes are inadequate for varicella-zoster infection. 1
- Antiviral medications do not eradicate latent virus but control symptoms and reduce complications. 1
Pain Management
Acute Pain Control
Acute zoster pain requires multimodal analgesia:
- Over-the-counter analgesics: Acetaminophen and ibuprofen for mild-to-moderate pain 1
- Gabapentin: First-line agent for neuropathic pain, titrated to 2400 mg/day in divided doses (expect somnolence in ~80% of patients) 1
- Pregabalin: May be added for uncontrolled pain, particularly in postherpetic neuralgia 1
- Topical therapies: Single application of 8% capsaicin patch provides analgesia lasting ≥12 weeks; pretreat with 4% lidocaine for 60 minutes to mitigate burning 1
- Tricyclic antidepressants (e.g., amitriptyline): May help control neuropathic pain in low doses 5
Topical ice or cold packs can reduce pain and swelling during the acute phase. 1
Postherpetic Neuralgia Prevention
Early antiviral therapy within 72 hours significantly reduces the risk of postherpetic neuralgia. 3, 4 Gabapentin or pregabalin initiated during the acute phase may provide additional benefit. 1
Role of Corticosteroids
Corticosteroids are NOT routinely recommended for shingles treatment. 6
The evidence is mixed:
- Prednisone may provide modest benefits in reducing acute zoster pain when used as adjunctive therapy to antivirals in select cases of severe, widespread shingles. 1
- However, corticosteroids carry significant risks (infections, hypertension, myopathy, glaucoma, osteopenia, Cushing syndrome) that generally outweigh benefits, particularly in elderly patients who are most susceptible to shingles. 1
- Corticosteroids should be avoided in immunocompromised patients due to increased risk of disseminated infection. 1
Absolute contraindications to prednisone: Poorly controlled diabetes, history of steroid-induced psychosis, severe osteoporosis, prior severe steroid toxicity. 1
If corticosteroids are used, the typical regimen is prednisone 60 mg daily for 7 days, started concurrently with antivirals within 72 hours of rash onset. 1
Special Populations
Immunocompromised Patients
Immunocompromised patients require aggressive management:
- Uncomplicated herpes zoster: Oral acyclovir 800 mg five times daily or valacyclovir 1000 mg three times daily, with consideration for higher doses or extended duration 1
- Disseminated or invasive disease: IV acyclovir 10 mg/kg every 8 hours with temporary reduction in immunosuppressive medications if clinically feasible 1
- Monitor closely for visceral dissemination (pneumonia, hepatitis, CNS involvement) 1
For patients on proteasome inhibitors (e.g., bortezomib) or JAK inhibitors, consider acyclovir prophylaxis (400 mg daily) to prevent herpes zoster. 1
Pregnant Women
For pregnant patients with serious VZV complications (e.g., pneumonia), initiate IV acyclovir. 1 Varicella-zoster immune globulin (VZIG) is recommended for VZV-susceptible pregnant women within 96 hours after exposure. 1
Facial/Ophthalmic Involvement
Facial zoster requires urgent treatment due to risk of cranial nerve complications:
- Start oral valacyclovir 1000 mg three times daily or famciclovir 500 mg three times daily within 72 hours 1
- Elevate the affected area to promote drainage 1
- Keep skin well hydrated with emollients 1
- Refer to ophthalmology immediately for suspected ophthalmic involvement 5
Acyclovir-Resistant Herpes Zoster
Suspect resistance when lesions fail to improve within 7–10 days of appropriate therapy. 1
Confirmed acyclovir-resistant VZV (rare in immunocompetent patients, up to 7% in immunocompromised):
- Foscarnet 40 mg/kg IV every 8 hours until clinical resolution (treatment of choice) 1
- All acyclovir-resistant strains are also resistant to valacyclovir, and most to famciclovir 1
- Topical cidofovir gel 1% applied once daily for 5 days may be an alternative 1
Obtain viral culture with susceptibility testing to confirm resistance. 1
Infection Control
Patients with herpes zoster are contagious until all lesions have crusted:
- Avoid contact with susceptible individuals (those without chickenpox history or vaccination) 1
- Cover lesions with clothing or dressings to minimize transmission 1
- Healthcare workers with herpes zoster should be excluded from duty until all lesions dry and crust 1
- For disseminated zoster or immunocompromised patients, implement both airborne and contact precautions 1
VZV transmission occurs only through direct contact with vesicular fluid; exposed seronegative individuals develop chickenpox, not shingles. 7
Vaccination Recommendations
The recombinant zoster vaccine (Shingrix) is strongly recommended for all adults ≥50 years, regardless of prior herpes zoster episodes. 1, 8
Vaccination Schedule
- Standard regimen: Two doses given 2–6 months apart (minimum interval 4 weeks) 8
- Immunocompromised adults ≥18 years: Shortened schedule with second dose at 1–2 months 8
- After a shingles episode: Wait at least 2 months after symptom resolution before vaccinating 8
- After Zostavax: Wait at least 2 months before starting Shingrix series 8
Shingrix demonstrates 97.2% efficacy in preventing herpes zoster, with protection persisting for at least 8 years (>83.3% efficacy). 8 This is vastly superior to Zostavax, which declines to only 14.1% efficacy by year 10. 8
Shingrix is safe for immunocompromised patients (unlike live Zostavax, which is contraindicated). 8 Common side effects include injection-site reactions (9.5%) and systemic symptoms (11.4%), which are transient and resolve within ~4 days. 8
Monitoring During Treatment
For IV acyclovir therapy:
- Assess renal function at initiation and monitor once or twice weekly 1
- Watch for thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in immunocompromised patients 1
- Adjust dosing for any renal impairment 1
For all patients: